Chemotherapy regimen | PLD group | Epirubicin group |
---|---|---|
Neoadjuvant chemotherapy | 70 | 204 |
 PLD/Epirubicin+C, n (%) | 7 (10.0%) | 23 (11.3%) |
 PLD/Epirubicin+C-T, n (%) | 28 (40.0%) | 33 (16.2%) |
 PLD/Epirubicin+T, n (%) | 14 (20.0%) | 53 (26.0%) |
 T + PLD/Epirubicin+C, n (%) | 25 (38.5%) | 62 (30.4%) |
 others, n (%) | 9 (12.9%) | 33 (16.2%) |
Adjuvant chemotherapy | 292 | 647 |
 PLD/Epirubicin+C, n (%) | 88 (30.1%) | 66 (10.2%) |
 PLD/Epirubicin+C + T, n (%) | 22 (7.5%) | 68 (10.5%) |
 PLD/Epirubicin+C-T, n (%) | 136 (46.6%) | 255 (39.4%) |
 C + PLD/Epirubicin+F, n (%) | 1 (0.3%) | 0 (0.0%) |
 T + PLD/Epirubicin, n (%) | 20 (6.9%) | 198 (30.6%) |
 T-PLD/Epirubicin+C, n (%) | 8 (2.7%) | 25 (3.9%) |